米氮平联合低频重复经颅磁刺激治疗激越性抑郁症对照研究

目的：探讨米氮平联合低频重复经颅磁刺激治疗激越性抑郁症的临床疗效和安全性。方法将60例激越性抑郁症患者随机分为两组，每组30例，两组均口服米氮平治疗，研究组联合低频重复经颅磁刺激治疗，观察4周。采用汉密顿抑郁量表及大体评定量表评定临床疗效，副反应量表评定不良反应。结果研究组治疗第1周、2周末汉密顿抑郁量表及大体评定量表评分均显著低于对照组（ P＜0．05或0．01）；治疗第4周末研究组显效率86．7％、有效率96．7％，对照组分别为90．0％、93．3％，两组比较差异无显著性（χ^2＝0．16、0．35，P＞0．05）。两组不良反应较轻微，发生率比较差异无显著性（P＞0．05）。结论米氮平联合低频重复经颅磁刺激治疗激越性抑郁症疗效显著，起效快，安全性高，有利于提高患者的治疗依从性，优于单用米氮平治疗。

A control study of mirtazapine plus low-frequency rTMS in agitated depression

Objective To explore the efficacy and safety of mirtazapine plus low-frequency （LF） repetitive transcranial magnetic stimulation （rTMS） in agitated depression （AD） .Methods Sixty AD patients were randomly divided into two groups of 30 ones each ,both groups took orally mirtazapine ,research group was plus LF-rTMS for 4 weeks .Clinical efficacies were assessed with the Hamilton Depression Scale （HAMD） and Global Assessment Scale （GAS） and adverse reactions with the Treatment Emergent Symp-tom Scale （TESS） .Results The HAMD and GAS score were significantly lower in research than control group at the end of the 1st and 2nd week （P〈0 .05 or 0 .01）;at the end of the 4th week obvious effective and effective rate were respectively 86 .7% and 96 .7% in research and 90 .0% and 93 .3% in control group , which showed no significant group differences （χ^2 = 0 .16 ,0 .35 ;P〉 0 .05） .Adverse reactions of both groups were mild and their incidences had no significant group differences （P〉0 .05） .Conclusion Mirtazapine plus LF-rTMS has an evident effect ,takes effect more rapidly ,has higher safety ,and is more beneficial to improving patients’ treatment compliance compared with mirtazapine monotherapy in depression .